![](/img/cover-not-exists.png)
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
Sockel, K., Bornhaeuser, M., Mischak-Weissinger, E., Trenschel, R., Wermke, M., Unzicker, C., Kobbe, G., Finke, J., Germing, U., Mohr, B., Greiner, J., Beelen, D., Thiede, C., Ehninger, G., PlatzbeckeVolume:
97
Language:
english
Journal:
Haematologica
DOI:
10.3324/haematol.2012.067629
Date:
September, 2012
File:
PDF, 1.04 MB
english, 2012